Novavax, Inc.s in-depth stock price analysis indicates that the stock price has rallied 3.88% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -81.34% . Looking at the past 52 week period, the stock price is down -70.93% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Novavax, Inc. has a negative value of -75.58 compared to overall market performance. Stocks of Novavax, Inc. (NASDAQ:NVAX) rallied by 0.75% during the past week but lost 6.29% on a 4-week basis. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.06%. Novavax, Inc. (NASDAQ:NVAX) has underperformed the index by 7.97% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Novavax, Inc. (NASDAQ:NVAX) : On Friday heightened volatility was witnessed in Novavax, Inc. (NASDAQ:NVAX) which led to swings in the share price. The stock opened for trading at $1.33 and hit $1.37 on the upside , eventually ending the session at $1.34, with a gain of 1.52% or 0.02 points. The heightened volatility saw the trading volume jump to 6,034,684 shares. The 52-week high of the share price is $8.49 and the company has a market cap of $363 million. The 52-week low of the share price is at $1.16 .
Novavax Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $-0.26. The company had revenue of $3.20 million for the quarter, compared to analysts expectations of $4.12 million. The companys revenue was down -50.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.12 EPS.
Company has reported several Insider transactions to the SEC, on Feb 2, 2017, John Trizzino (SVP, Commercial Operations) purchased 3,401 shares at 1.12 per share price.On Feb 2, 2017, John A Iii Herrmann (SVP, General Counsel) purchased 4,960 shares at 1.12 per share price.On Feb 2, 2017, Barclay A Phillips (CFO) purchased 1,633 shares at 1.12 per share price.
NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on womens health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.